Bessemer Group Inc. boosted its stake in Iqvia Holdings Inc (NYSE:IQV) by 268.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 821 shares of the medical research company’s stock after purchasing an additional 598 shares during the quarter. Bessemer Group Inc.’s holdings in Iqvia were worth $132,000 as of its most recent filing with the SEC.
Other institutional investors also recently added to or reduced their stakes in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Iqvia by 7.0% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,251 shares of the medical research company’s stock valued at $1,331,000 after acquiring an additional 608 shares in the last quarter. GYL Financial Synergies LLC acquired a new stake in Iqvia in the first quarter valued at $4,349,000. Globeflex Capital L P raised its holdings in Iqvia by 96.6% in the first quarter. Globeflex Capital L P now owns 10,784 shares of the medical research company’s stock valued at $1,551,000 after acquiring an additional 5,299 shares in the last quarter. Meridian Wealth Advisors LLC raised its holdings in Iqvia by 13.0% in the first quarter. Meridian Wealth Advisors LLC now owns 4,197 shares of the medical research company’s stock valued at $604,000 after acquiring an additional 482 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Iqvia by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 2,130,570 shares of the medical research company’s stock valued at $247,087,000 after acquiring an additional 164,811 shares in the last quarter. Hedge funds and other institutional investors own 92.29% of the company’s stock.
In related news, insider Kevin C. Knightly sold 6,945 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $158.53, for a total value of $1,100,990.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ari Bousbib sold 96,000 shares of the stock in a transaction dated Wednesday, June 19th. The shares were sold at an average price of $150.00, for a total transaction of $14,400,000.00. The disclosure for this sale can be found here. Insiders sold a total of 198,945 shares of company stock valued at $30,860,991 in the last quarter. 6.00% of the stock is currently owned by insiders.
Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $1.39 EPS for the quarter, topping the consensus estimate of $1.38 by $0.01. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The company’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.29 earnings per share. As a group, sell-side analysts forecast that Iqvia Holdings Inc will post 5.86 earnings per share for the current year.
Several analysts recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Iqvia from $160.00 to $180.00 and gave the company an “overweight” rating in a report on Thursday, July 25th. Svb Leerink assumed coverage on shares of Iqvia in a report on Tuesday, May 28th. They issued an “outperform” rating and a $160.00 price target on the stock. Morgan Stanley increased their target price on shares of Iqvia from $156.00 to $170.00 and gave the stock an “overweight” rating in a report on Wednesday, June 19th. Leerink Swann assumed coverage on shares of Iqvia in a report on Tuesday, May 28th. They set an “outperform” rating and a $136.38 target price on the stock. Finally, Barclays set a $180.00 target price on shares of Iqvia and gave the stock a “buy” rating in a report on Monday, July 15th. Three research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $161.13.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: Liquidity
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.